XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.22.2

Financing (Tables) | 6 Months Ended
--- | ---
Jul. 01, 2022
Debt Disclosure [Abstract] |
Components of Debt | The components of the Company’s debt were as follows ($ in millions):
Description and Aggregate Principal Amount |  | July 1, 2022 |  | December 31, 2021
U.S. dollar-denominated commercial paper |  | $ | — |  |  | $ | 1,440 |
Euro-denominated commercial paper (€1.9 billion and €1.2 billion, respectively) |  | 2,008 |  |  | 1,366 |
Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”) |  | — |  |  | 284 |
2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”) |  | 700 |  |  | 699 |
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) |  | 563 |  |  | 592 |
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) |  | 936 |  |  | 1,021 |
2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”) |  | 698 |  |  | 698 |
3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”) |  | 498 |  |  | 498 |
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) |  | 1,298 |  |  | 1,416 |
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) |  | 832 |  |  | 907 |
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) |  | 227 |  |  | 267 |
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) |  | 624 |  |  | 680 |
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) |  | 1,296 |  |  | 1,413 |
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) |  | 222 |  |  | 233 |
2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”) |  | 796 |  |  | 795 |
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) |  | 834 |  |  | 910 |
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) |  | 1,814 |  |  | 1,980 |
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) |  | 392 |  |  | 461 |
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) |  | 1,288 |  |  | 1,406 |
3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”) |  | 890 |  |  | 890 |
4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”) |  | 499 |  |  | 499 |
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) |  | 773 |  |  | 844 |
3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”) |  | 889 |  |  | 889 |
2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”) |  | 980 |  |  | 980 |
2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”) |  | 984 |  |  | 983 |
Other |  | 21 |  |  | 25 |
Total debt |  | 20,062 |  |  | 22,176 |
Less: currently payable |  | (10) |  |  | (8) |
Long-term debt |  | $ | 20,052 |  |  | $ | 22,168 |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69E -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration